Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

NCT03552380 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Funder halted development of compound in this disease

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Entinostat
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Roberto Pili

Collaborators

[object Object]
[object Object]
[object Object]